RNA drug maker grew revenue 85% to $1.1B but trades at 70x earnings — classic Lynch fast grower discovered too late.
At 0.35% earnings yield, Alnylam's pendulum has swung from -$405M losses to euphoria at 70x earnings.
What does this company do and how does it make money?
Alnylam operates a highly concentrated biotech model with just two RNA interference drugs driving all product revenue. The 85% revenue growth and 75.6% gross margins demonstrate strong pricing power in specialized therapeutics, but the narrow product portfolio creates binary risk around these two assets.
Five legendary investment frameworks analyzed this company.
Lynch sees a classic fast grower with 85% revenue growth and insider buying, while Marks sees a 70x earnings pendulum at its euphoric peak. The tie-breaker? Whether you believe management or the institutions heading for the exits. Tap any framework card below to explore their complete analysis and specific position on Alnylam.
How much cash does it generate and where does it go?
Alnylam channels every dollar of cash flow — and then some — into R&D, spending 110-228% of operating cash in positive quarters. This aggressive reinvestment strategy reflects confidence in the pipeline but creates significant cash flow volatility as the company prioritizes future growth over current returns.
Is the business getting stronger or weaker?
Alnylam has executed a dramatic turnaround from deep losses to sustained profitability in just 2.5 years. The combination of 85% revenue growth, expanding operating margins, and consistent 75%+ gross margins signals a business hitting its commercial stride after years of development-stage losses.
What could go wrong and has it survived trouble before?
Alnylam's extreme concentration in two products creates binary risk — any setback to GIVLAARI or ONPATTRO could devastate results. The ownership divergence, with management buying while institutions sell, suggests disagreement about whether current 70x earnings adequately prices these concentration risks.
From -$405M quarterly losses to +$186M profits in 2.5 years — but at 70.52x earnings, the market already priced in the miracle.
Is the stock priced for perfection, fair value, or pessimism?
At 70.52x earnings, the market has already priced in Alnylam's profitability miracle. The 0.35% earnings yield offers virtually no cushion for disappointment, while the implied 5.16% perpetual growth rate seems conservative against 85% current growth but may reflect concerns about the two-product concentration.
Analysis applies published investment frameworks to publicly available financial data. Educational purposes only. Not financial advice.